OakChart

Trinity Biotech Plc ADR

TRIBHealthcare·Medical Devices·Ireland·Nano·NASD·Nov 11 • 2:33 PM ET

5.84-0.04 (-0.60%)
2026-11-11 20:54 CET
Market cap
3.79 USD m
Revenue, TTM
47.13 USD m
Net income, TTM
-33.04 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-52.93
P/E
-
Compare

Price

TRIB against its 20, 50 and 200-day averages
2050200
5.0010.0015.0020.0025.00843K1.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TRIBclose 5.8520-day 6.8450-day 7.08200-day 14.715.85

88.9% under the 52-week high of 52.50 on 23 Dec 2025. 52-week low 5.00 on 5 Nov 2026. Last 15 sessions, 59.1% high to low

Profile

TRIB
52-week range, 2% of the way up
5.0052.50

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World-Ireland geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Employees287
IPOOct 21, 1992
Beta0.99
ATR, 14d0.73
Rel volume0.38
Short float3.39%
Insider own3.57%
Inst own4.28%

Snapshot

6 groups

Valuation

Index-
Market Cap3.74M
Enterprise Value136.58M
Income-33.04M
Sales47.13M
Book/sh-111.67
Cash/sh8.03
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJun 05, 2015
Dividend Gr. 3/5Y- -
Payout-
Employees287
IPOOct 21, 1992

Ratios

P/E-
Forward P/E-
PEG-
P/S0.08
P/B-
P/C0.73
P/FCF-
EV/EBITDA-
EV/Sales2.90
Quick Ratio0.12
Current Ratio0.25
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-52.93
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y30.77% -5.58%
Sales past 3/5Y-11.12% -15.62%
EPS Y/Y TTM39.65%
Sales Y/Y TTM-13.28%
EPS Q/Q52.53%
Sales Q/Q43.08%
Earnings-
EPS/Sales Surpr.-311.83% -3.90%

Ownership

Insider Own3.57%
Insider Trans0.00%
Inst Own4.28%
Inst Trans-1.51%
ROA-35.91%
ROE-
ROIC-
Gross Margin32.95%
Oper. Margin-23.88%
Profit Margin-70.10%
SMA20-14.61%
SMA50-17.39%
SMA200-60.26%
Trades-

Technical

Shs Outstand0.64M
Shs Float0.62M
Short Float3.39%
Short Ratio1.11
Short Interest0.02M
52W High52.50 -88.87%
52W Low5.00 16.90%
Volatility13.88% 11.88%
ATR (14)0.73
RSI (14)39.80
Beta0.99
Rel Volume0.38
Avg Volume18.94K
Volume5,972

Performance

Perf Week-9.06%
Perf Month-7.22%
Perf Quarter-50.76%
Perf Half Y-66.98%
Perf YTD-75.37%
Perf Year-78.36%
Perf 3Y-90.78%
Perf 5Y-98.02%
Perf 10Y-99.42%
Recom1.00
Target Price450.00
Prev Close5.88
Price5.84
Change %-0.60%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 23, 2015DowngradeCCraig HallumBuy → Hold
Sep 03, 2015InitiatedRRaymond JamesOutperform
Jul 29, 2015ReiteratedRROTH CapitalBuy$22 → $20+242.2%
Jul 22, 2008ReiteratedRRoth CapitalBuy$7 → $6+2.7%
Mar 17, 2008ReiteratedRRoth CapitalBuy$10.50 → $7+19.8%
Dec 10, 2007ReiteratedRRoth CapitalBuy$11.50 → $10.50+79.6%
Oct 26, 2007ReiteratedRRoth CapitalBuy$13 → $11.50+96.7%

Peers

Mkt cap
TickerCompanyMkt cap
BMRABiomerica Inc6.99M
CODXCo-Diagnostics Inc2.48M
QDELQuidelOrtho Corp806.24M
BJDXBluejay Diagnostics Inc2.96M
OSUROrasure Technologies Inc246.85M
SENSSenseonics Holdings Inc569.44M
PRPOPrecipio Inc43.82M
MDXHMDxHealth SA14.51M
XGNExagen Inc120.46M

News

latest 14 of 200
  • Trinity Biotech's Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure (GlobeNewswire) -11.70%
  • Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update (GlobeNewswire)
  • Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure (GlobeNewswire)
  • Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
  • Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology (GlobeNewswire) -15.44%
  • Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
  • New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring (GlobeNewswire) +5.49%
  • Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling (GlobeNewswire) -6.94%
  • Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville (GlobeNewswire) +15.73%
  • TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today (Stocktwits) -38.95%
  • Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market (GlobeNewswire)
  • Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results (GlobeNewswire) -15.83%
  • Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations (GlobeNewswire)
  • Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test (GlobeNewswire) -5.14%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q12025-05-21-17.100--14.4357.50--
2024Q42025-05-15-37.065-9.000-38.37015.8616.501
2024Q32024-11-15-13.746-16.200-13.78515.1516.501
2024Q22024-08-14-21.417-20.100-21.39315.8415.001
2024Q12024-05-23-11.220--11.18814.70--
2023Q42024-04-04-107.67--21.71613.43--
2023Q32024-01-31-26.250-22.500-26.16714.6814.501
2023Q22023-10-03-71.883-13.500-23.43113.9013.501
2023Q12023-07-06-24.786-9.000-22.93714.8318.501
2022Q42023-03-23-39.750-9.000-40.02918.0418.001
2022Q32022-12-15-35.205-6.000-35.03019.5019.501
2022Q22022-11-03-42.870-43.500-42.59918.4618.461
2022Q12022-06-30-11.730-6.000-74.75318.7820.001
2021Q42022-04-119.54010.50010.87919.5324.001
2021Q32021-12-167.33512.0000.25022.0024.251
2021Q22021-09-0931.80010.50029.62125.8424.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY60.30082.02671.610100.2100.97
2016FY33.60041.499-658.0999.61101.69
2017FY38.55023.250-284.9199.1498.85
2018FY39.00034.500-158.3497.0496.01
2019FY-0.450--207.4690.44-
2020FY112.3581.000-46.15010297.22
2021FY51.57069.0004.91892.9797.44
2022FY-182.4-106.5-182.4574.7874.74
2023FY-144.49--94.27456.83-
2024FY-52.144-52.200-53.10061.5662.20
2025FY--53.100-60.547-47.50
2026FY--32.700--59.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q2S2025-06-1010110.5010.5010.50
2025Q2S2025-01-2910017.5017.5017.50
2025Q2S2024-11-1511017.5017.5017.50
2025Q2S2024-08-1410017.0017.0017.00
2025Q2S2024-06-1410017.0017.0017.00
2025Q2S2024-06-1310017.0017.0017.00
2025Q2S2024-06-1210017.0017.0017.00
2025Q2S2024-06-1110017.0017.0017.00
2025Q2E2025-06-10101-0.51-0.51-0.51
2025Q2E2025-01-29100-0.24-0.24-0.24
2025Q2E2024-11-15110-0.24-0.24-0.24
2025Q2E2024-08-14100-0.31-0.31-0.31
2025Q2E2024-06-14100-0.31-0.31-0.31
2025Q2E2024-06-13100-0.31-0.31-0.31

Estimate history

EPS, annual-284.914-158.343-207.459-46.154.918-182.446-94.274-53.006-60.547-52.9312
Period201720182019202020212022202320242025TTM
EPS, quarterly-11.188-21.393-13.785-38.092-14.435-9.735-8.219-28.125-6.853
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual100.16496.93190.418102.65692.81962.55556.9261.44643.9247.13
Period201720182019202020212022202320242025TTM
Sales, quarterly14.66915.82715.19515.7447.57610.97614.24711.06410.839
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.140.1390.1390.1390.1390.2540.2560.620.645
Period201720182019202020212022202320242025
Shares, quarterly0.2550.2550.3790.620.6020.6210.6210.645-
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue47.1343.9261.4556.9262.5692.82102.6690.4296.93
Cost of Goods Sold Incl. D&A-28.3741.2338.3946.2055.7255.1754.6758.35
Gross Profit-15.5520.2218.5316.3537.1047.4935.7538.58
Selling, General and Administrative Excl. Other-26.5131.7433.8231.1528.7429.2930.7933.23
Research and Development-3.644.534.394.144.495.115.325.36
Other Operating Expense-0.000.000.000.480.580.571.380.00
Operating Income--10.96-11.52-15.28-15.287.7817.643.585.35
Interest Expense-21.459.5511.0724.757.096.805.585.07
Unusual Expense-4.399.2711.615.631.9616.9927.7223.91
Net Income Before Taxes--37.29-30.68-36.98-43.800.75-6.68-29.99-23.16
Income Taxes-0.200.49-0.06-0.19-0.18-0.62-1.01-0.52
Consolidated Net Income-33.04-37.49-31.16-36.93-43.610.93-6.05-28.99-22.63
Net Income From Continuing Operations-33.04-37.49-31.16-36.93-43.610.93-6.05-28.99-22.63
Net Income-33.04-37.49-31.73-24.06-41.030.87-6.43-28.91-22.07
EPS (Recurring)--55.59-42.17-62.43-164.9312.6539.18-68.20-38.24
EPS (Basic, Before Extraordinaries)-52.93-60.55-53.01-94.27-182.456.27-46.15-207.46-158.34
EPS (Diluted)-52.93-60.55-53.01-94.27-182.454.92-46.15-207.46-158.34
EBITDA--8.26-9.66-13.50-12.9410.5220.738.479.46
Non-Operating Income (Expense)--0.50-0.340.981.852.01-0.53-0.270.48
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.281.151.811.540.960.700.661.20
Price To Earnings Ratio-----3.545.72-15.58
Price To Sales Ratio-0.330.260.290.530.410.780.240.49
Gross Margin-35.4032.9032.5626.1439.9746.2639.5339.80
Operating Margin--24.94-18.75-26.85-24.428.3817.183.965.52
Net Margin-70.10-85.36-51.64-42.26-65.590.94-6.26-31.97-22.76
Shares Outstanding-0.640.620.260.250.140.140.140.14
Market Capitalization3.793.7916.3616.3937.7329.8979.6321.6047.86

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue10.8411.0614.2510.987.5815.7415.2015.83
Cost of Goods Sold Incl. D&A-7.528.166.656.0111.0110.2110.32
Gross Profit-3.556.094.331.574.734.985.51
Selling, General and Administrative Excl. Other-6.496.627.376.309.657.217.19
Research and Development-1.060.810.651.121.441.010.99
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income--2.94-0.54-3.04-4.73-4.91-2.23-1.68
Interest Expense-12.664.272.152.314.253.092.83
Unusual Expense-3.860.270.551.762.840.342.38
Net Income Before Taxes--17.64-5.04-5.75-8.80-15.68-4.81-6.88
Income Taxes--0.170.070.300.010.58-0.04-0.13
Consolidated Net Income-4.42-17.46-5.11-6.05-8.80-16.27-4.77-6.75
Net Income From Continuing Operations-4.42-17.46-5.11-6.05-8.80-16.27-4.77-6.75
Net Income-4.42-17.46-5.11-6.05-8.80-16.83-4.77-6.75
EPS (Recurring)--23.78-7.92-9.11-12.42-33.58-13.10-16.11
EPS (Basic, Before Extraordinaries)-6.85-28.13-8.22-9.73-14.43-38.09-13.79-21.39
EPS (Diluted)-6.85-28.13-8.22-9.73-14.43-38.09-13.79-21.39
EBITDA--2.210.12-2.38-4.09-4.49-1.63-1.53
Non-Operating Income (Expense)-1.820.03-0.000.00-3.670.850.01
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.030.050.080.110.120.220.26
Price To Sales Ratio-0.340.400.240.190.190.190.34
Gross Margin-32.0542.7239.4520.6730.0732.8034.82
Operating Margin--26.60-3.77-27.73-62.47-31.20-14.64-10.60
Net Margin-40.74-157.84-35.88-55.09-116.21-106.92-31.41-42.65
Shares Outstanding-0.640.620.620.600.620.380.25
Market Capitalization3.7915.3019.3812.1110.2916.3612.5116.28

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.145.173.696.5825.9127.3316.4030.2857.61
Short Term Receivables10.2814.6013.3815.6515.7124.5922.3925.2219.18
Inventories18.8319.3719.9322.5029.1230.2232.0230.3632.80
Other Current Assets1.651.982.041.931.951.160.580.813.00
Total Current Assets35.9041.1239.0446.6772.6983.3071.3986.66112.59
Net Property, Plant & Equipment5.304.621.895.685.928.559.295.365.80
Total Investments and Advances3.022.620.180.130.000.150.000.000.36
Long-Term Note Receivable-0.000.040.080.150.290.400.480.68
Intangible Assets56.9951.3416.2735.2735.9833.8643.6552.9564.75
Deferred Tax Assets3.923.551.984.224.104.186.256.138.70
Other Assets0.030.030.040.060.060.060.080.080.09
Total Assets105.17103.2959.4492.10118.89130.40131.07151.66192.97
Short Term Debt Incl. Current Port. of LT Debt110.812.501.901.8985.292.152.400.440.35
Accounts Payable11.486.833.886.206.767.107.838.128.04
Income Tax Payable0.350.360.280.030.020.150.050.210.31
Other Current Liabilities18.5722.408.979.228.4117.659.168.8412.52
Total Current Liabilities141.2132.0915.0417.34100.4927.0619.4517.6021.23
Long Term Debt27.1798.2765.5270.3113.8799.2899.7781.9193.49
Provision for Risks Charges0.780.070.000.000.000.000.000.000.00
Deferred Tax Liabilities4.674.562.305.064.864.907.147.8510.83
Other Liabilities3.323.470.531.570.001.370.000.242.23
Total Liabilities177.15138.4783.3894.28119.21132.62126.36107.61127.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-71.98-35.18-23.95-2.18-0.32-2.224.7144.0565.20
Total Shareholders Equity-71.98-35.18-23.95-2.18-0.32-2.224.7144.0565.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-71.98-35.18-23.95-2.18-0.32-2.224.7144.0565.20
Total Liabilities & Stockholders Equity105.17103.2959.4492.10118.89130.40131.07151.66192.97
Book Value Per Share-111.67-56.78-93.73-8.57-2.29-15.9233.82316.15467.26
Tangible Book Value Per Share-200.07-139.65-157.40-147.39-260.51-258.92-279.46-63.853.17
Full-Time Employees287401380384477543---
Price to Book Ratio-0.05-0.47-0.945.69-93.70-35.894.581.090.98
Return on Assets-35.97-38.30-48.73-41.340.74-4.63-20.50-13.13-17.60
Return on Equity------485.39-118.87-41.43-44.76
Return on Invested Capital--50.30-57.86-60.226.45-6.62-27.67-17.52-25.64
Quick Ratio0.120.681.271.390.431.962.023.203.76
Current Ratio0.251.282.602.690.723.083.674.925.30

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--37.49-31.73-24.06-41.030.87-6.43-28.91-22.07
Depreciation-2.691.861.782.332.743.104.894.12
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-22.1215.385.7631.5210.5224.1427.8028.06
Funds from Operations--12.68-14.49-16.51-7.1814.1320.813.7810.11
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-6.424.07-2.70-1.66-5.75-0.92-2.36-7.38
Cash from Operating Activities--6.26-10.43-19.21-8.848.3819.891.422.72
Capital Expenditures--6.24-10.05-2.71-5.98-8.68-10.27-11.85-17.37
Net Assets From Acquisitions-0.00-12.880.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.0028.200.000.000.000.00-
Purchase or Sale of Investments-0.000.00-0.700.000.000.000.000.00
Purchase of Investments-0.000.00-0.700.000.000.000.000.00
Sale Or Maturity of Investments-0.000.00-0.000.000.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--6.24-22.9324.79-5.98-8.68-10.27-11.85-17.37
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-0.557.380.0025.410.000.000.00-0.43
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.00-0.43
Sale of Common Pref Stock-0.557.380.0025.410.000.000.000.00
Proceedsfrom Stock Options-0.557.380.0025.410.000.000.000.00
Issuance or Reduction of Debt, Net-15.0530.12-6.11-27.061.760.000.00-11.92
Change in Long Term Debt-15.0530.12-6.1159.720.000.000.00-11.92
Issuance of Long Term Debt-15.0530.124.8697.710.000.000.000.48
Reduction of Long Term Debt-0.000.00-10.97-37.990.000.000.00-12.40
Net Financing Active Other Cash Flow-0.000.000.000.000.004.550.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-12.4035.00-8.43-4.41-1.171.29-3.53-12.36
Exchange Rate Effect-0.07-0.17-0.04-0.110.050.090.09-0.30
Net Change in Cash--0.031.47-2.89-19.34-1.4111.00-13.87-27.30
Free Cash Flow--6.34-10.83-20.01-9.946.5716.66-0.71-4.80
Price to Free Cash Flow-----5.794.78--

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments-5.141.341.554.075.17
Short Term Receivables-10.2815.0211.3211.1814.60
Inventories-18.8319.1620.1320.2719.37
Other Current Assets-1.65---1.98
Total Current Assets-35.9035.5233.0035.5241.12
Net Property, Plant & Equipment-5.304.014.314.384.62
Total Investments and Advances-3.022.802.832.672.62
Intangible Assets-56.9957.8155.9253.6651.34
Deferred Tax Assets-3.923.553.553.543.55
Other Assets-0.030.030.030.030.03
Total Assets-105.17103.7199.6399.79103.29
Short Term Debt Incl. Current Port. of LT Debt-110.812.342.512.442.50
Accounts Payable-29.7030.3526.4925.296.83
Income Tax Payable-0.350.490.470.390.36
Other Current Liabilities-0.351.312.062.3522.40
Total Current Liabilities-141.2134.4931.5230.4732.09
Long Term Debt-27.17114.86110.05105.5398.27
Provision for Risks Charges-0.780.070.070.070.07
Deferred Tax Liabilities-4.674.564.564.554.56
Other Liabilities-3.324.442.962.793.47
Total Liabilities-177.15158.43149.17143.41138.47
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value-0.000.000.000.000.00
Common Equity--71.98-54.72-49.54-43.62-35.18
Total Shareholders Equity--71.98-54.72-49.54-43.62-35.18
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity--71.98-54.72-49.54-43.62-35.18
Total Liabilities & Stockholders Equity-105.17103.7199.6399.79103.29
Book Value Per Share--111.67-88.10-79.76-72.49-56.78
Tangible Book Value Per Share--200.07-181.18-169.80-161.65-139.65
Full-Time Employees-287---401
Price to Book Ratio--0.21-0.35-0.24-0.24-0.47
Return on Assets--35.91-36.02-37.00-38.50-38.22
Return on Invested Capital---8.50-9.99-14.22-26.68
Quick Ratio-0.120.470.410.500.68
Current Ratio-0.251.031.051.171.28

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income--17.51-5.10-6.08-8.80-16.96
Depreciation-0.730.660.670.640.42
Other Funds (Non Cash)-13.503.822.662.1413.39
Funds from Operations--3.28-0.62-2.75-6.03-3.15
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-1.730.551.083.076.42
Cash from Operating Activities--1.55-0.07-1.67-2.963.28
Capital Expenditures--0.80-1.46-2.00-1.98-2.74
Net Assets From Acquisitions-0.000.000.000.00-0.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--0.80-1.46-2.00-1.98-2.74
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock--0.00-0.000.000.550.54
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock--0.00-0.000.000.550.54
Proceedsfrom Stock Options--0.00-0.000.000.550.54
Issuance or Reduction of Debt, Net-7.012.141.894.002.00
Change in Long Term Debt-7.012.141.894.002.00
Issuance of Long Term Debt-7.011.982.054.002.00
Reduction of Long Term Debt-0.000.15-0.150.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.00
Cash from Financing Activities-6.151.341.093.811.88
Exchange Rate Effect-0.010.000.030.03-0.09
Net Change in Cash-3.81-0.19-2.55-1.102.33
Free Cash Flow--1.54-0.08-1.71-3.023.12

Revenue breakdown

Clinical Laboratory2024: 39.37M 2025: 31.68M
Laboratory Services2024: 4.75M 2025: 4.01M
Point-of-Care2024: 17.43M 2025: 8.10M
Eliminations2024: -20.52M 2025: -23.19M
Ireland2024: 20.47M 2025: 15.00M
United States2024: 61.61M 2025: 51.98M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.39%0.0M0.6M18.97K
2026-10-155.06%0.0M0.6M22.52K
2026-09-302.88%0.0M0.6M22.22K
2026-09-151.29%0.0M0.6M58.99K
2026-08-311.59%0.0M0.6M56.67K
2026-08-141.50%0.0M0.6M52.77K
2026-07-312.76%0.0M0.6M48.63K
2026-07-151.95%0.0M0.6M43.73K
2026-06-307.60%0.0M0.6M41.23K
2026-06-150.78%0.0M0.6M4.54K
2026-05-291.29%0.0M0.6M5.25K
2026-05-151.30%0.0M0.6M5.22K
2026-04-301.25%0.0M0.6M5.89K
2026-04-152.24%0.0M0.6M8.03K
2026-03-311.62%0.0M0.6M8.91K
2026-03-131.12%0.0M0.6M109.70K
2026-02-271.38%0.0M0.6M107.00K
2026-02-131.38%0.0M0.6M106.55K
2026-01-301.42%0.0M0.6M105.87K
2026-01-151.96%0.0M0.6M102.36K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13D/ASEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-01EFFECTEffectiveness filing by commission orderSEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-28POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-27AWWithdrawal of amendment to a registration statement filed under the Securities ActSEC
2026-08-21F-1/ASEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-22SEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-22SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-23424B3SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-18424B3SEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-06-15424B3SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-12424B5SEC
2026-06-10EFFECTEffectiveness filing by commission orderSEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-06-04AWWithdrawal of amendment to a registration statement filed under the Securities ActSEC
2026-06-04POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-06-03RWRegistration Withdrawal RequestSEC
2026-06-03F-1/ASEC
2026-05-26424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC3.82%
Williams & Novak, LLC0.73%
Cambridge Investment Research Advisors, Inc.0.23%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.14%
Moss Adams Wealth Advisors LLC0.13%
INSPIRION WEALTH ADVISORS, LLC0.13%
RAYMOND JAMES FINANCIAL INC0.11%
BECKER CAPITAL MANAGEMENT INC0.09%
LPL Financial LLC0.09%
GEODE CAPITAL MANAGEMENT, LLC0.07%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.07%

OakChart. TRIB. Cached 15 minutes.

Some panels did not load: insider.